Group 1 - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [2] - The company's lead program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [2] - Vivoryon will participate in several upcoming medical and investor conferences, including the J.P. Morgan Healthcare Conference, UBS European Healthcare Conference, and World Congress of Nephrology [1] Group 2 - The J.P. Morgan Healthcare Conference will take place in San Francisco, USA from January 12-14, 2026 [1] - The UBS European Healthcare Conference is scheduled for March 3-4, 2026 in London, UK [1] - The World Congress of Nephrology will be held in Yokohama, Japan from March 28-31, 2026 [1]

Core Insights - Vivoryon Therapeutics N.V. will report its H1 2025 financial results and operational progress on September 4, 2025 [1] - The company focuses on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [3] Financial Reporting - The financial results will cover the period ended June 30, 2025, and will be available for download on the company's website [1] - A conference call and webcast will be held on the same day to discuss the results [2] Company Overview - Vivoryon is a clinical stage biotechnology company dedicated to innovative treatments for kidney-related inflammatory and fibrotic disorders [3] - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]